Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEsSimon Eschweiler, Christian H. Ottensmeier, Oliver Wood et al.|Nature|2022Cited by 91
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignanciesJohn N. Allan, Jennifer R. Brown, Javier Pinilla‐Ibarz et al.|Haematologica|2021Cited by 37
Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell MalignanciesJohn N. Allan, Jennifer R. Brown, Krish Patel et al.|Blood|2019Cited by 28